VIVIS Hires National Sales Team as New CBD Pain Cream Nears Launch Date

Rhea-AI Summary

Neutra Corporation (OTC PINK:NTRR) subsidiary VIVIS is enhancing its market presence with a new CBD pain cream and a nationwide sales team to support its launch. The cream features a 1000 mg broad spectrum CBD dosage, designed to alleviate chronic pain, which affects over 116 million Americans. Priced competitively with existing products, this offering aims to capture greater market share and generate additional revenue. CEO Sydney Jim emphasizes the cream's quality and potential popularity among both retailers and consumers, as it aligns with the growing demand for hemp-based solutions.

Positive

• Engaged a nationwide sales team to enhance market reach.
• New CBD pain cream targets a large customer base, addressing chronic pain issues.
• Product is lab-tested, assuring quality for retail customers.

Negative

• Dependence on the success of a single product for revenue growth.
• Entry into a highly competitive CBD market may pose challenges.

KATY, TX / ACCESSWIRE / December 3, 2020 / Neutra Corporation (OTC PINK:NTRR) subsidiary VIVIS is ramping up efforts to enter additional regional and national markets. The company has engaged a nationwide sales team and this group will soon be able to pitch a new VIVIS-branded CBD pain cream to customers and retail outlets, which is ready to hit the market.

"This new pain cream will be quite popular with stores and consumers alike," said Neutra CEO Sydney Jim. "It delivers superior relief for users through a broad spectrum CBD dosage of 1000 mg. Chronic pain sufferers can enjoy a respite and thus be more productive in their day-to-day lives. Retailers will be able to assure customers this pain cream is a quality, lab-tested product, just like all VIVIS offerings. And thanks to our new sales organization, our new CBD pain cream will reach a broader base, giving us additional revenue opportunities and greater market share."

As mentioned, VIVIS' pain cream comes in a 1000 mg broad spectrum dosage. It will be sold in a 1.7 oz. airless pump with pricing the same as the company's popular sports menthol cream.

According to a recent study, up to 116 million Americans suffer from chronic pain. Chronic pain costs victims more than $600 million in medical expenses and lost productivity. Worse, these patients often develop tolerance for conventional anti-pain medications, weakening their effectiveness over time. Hemp-based CBD products, such as those made by VIVIS, can alleviate such pain. Unlike CBD derived from cannabis, hemp-based CBD does not produce a high, thus it is legal for use in many states that outlaw cannabis.

To learn more about these and other VIVIS hemp-based CBD products, visit the company's website at http://viviscbd.com.

About Neutra Corp.

Neutra Corp. (NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.

NOTICE REGARDING FORWARD LOOKING STATEMENT

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Neutra Contact:

Sydney Jim
888-433-4033
info@neutrainc.com

SOURCE: Neutra Corp

View source version on accesswire.com:
https://www.accesswire.com/619250/VIVIS-Hires-National-Sales-Team-as-New-CBD-Pain-Cream-Nears-Launch-Date

FAQ

What new product is Neutra Corporation launching?

Neutra Corporation is launching a new VIVIS-branded CBD pain cream featuring a 1000 mg broad spectrum dosage.

How does the new CBD pain cream benefit consumers?

The CBD pain cream is designed to provide relief for chronic pain sufferers, which affects over 116 million Americans.

When is the VIVIS CBD pain cream expected to hit the market?

The CBD pain cream is ready to hit the market as the sales team prepares to promote it.

What is the pricing strategy for the new pain cream?

The pain cream will be priced the same as VIVIS's popular sports menthol cream.

What market potential does this product have?

Given the large number of chronic pain sufferers and the cost associated with pain management, the product has significant market potential.